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Summary
 
Strength of T cell receptor (TCR) signaling, coreceptors, costimulation, antigen-presenting
cell type, and cytokines all play crucial roles in determining the efficiency with which type 2 T
lymphocytes (Th2, Tc2) develop from uncommitted precursors. To investigate in vivo regula-
tory mechanisms that control the population of type 2 T cells and disease susceptibility, we
have created lines of transgenic mice in which expression of a chimeric cytokine receptor (the
mouse interleukin 2 receptor 
 
b
 
 chain [IL-2R
 
b
 
] extracellular domain fused to the cytoplasmic
 
tail of IL-4R
 
a
 
)
 
 
 
is targeted to the T lymphoid lineage using the proximal lck promoter. This
chimera transduced IL-4–specific signals in response to IL-2 binding and dramatically enhanced
type 2 responses (IL-4, IL-5, and immunoglobulin E production) upon in vitro TCR stimula-
tion or in vivo antigen challenge. Thus, type 2 effector function was augmented by IL-4 signals
transduced through a chimeric receptor expressed in a T cell–specific manner. This influence
was sufficient for establishment of antigen-induced allergic airway hyperresponsiveness on a
disease-resistant background (C57BL/6).
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I
 
nterleukin (IL)-4 is a pleiotropic cytokine that plays an
important role in the growth, differentiation, and sur-
vival of lymphocytes (1–4), as well as regulating other key
hematopoietic cells such as monocytes, macrophages, and
dendritic cells (5). One of the most important roles of IL-4
in immune regulation is its ability to influence the pheno-
type of effector T cells as they differentiate from naive pre-
cursors (1, 6–8). For instance, helper and cytolytic T lympho-
cytes can be divided into distinct subsets of effector cells
based on their functional capabilities and the profile of cy-
tokines they produce (9, 10). The Th1 subset of CD4
 
1
 
 T
cells secretes IFN-
 
g
 
 and TNF-
 
b
 
, which activate cell-medi-
ated immune responses optimally suited for immunity to
intracellular pathogens (11–13); the Tc1 subset of CD8
 
1
 
 cells
secretes similar cytokines. In contrast, the Th2 subset produces
IL-5, -6, -10, and -13, in addition to IL-4, and is associ-
ated with immune responses that combat extracellular mi-
crobes, in part through help to antibody responses (12, 13).
The mechanisms by which naive T precursor cells differ-
entiate into discrete effector cells remain a subject of inten-
sive investigation. Factors that control differentiation into
Th1 or Th2 cells include strength of signaling through the
TCR, antigen presentation (including antigen dose, route
of antigen administration, and type of APCs), involvement
of costimulatory pathways such as those activated by CD28
ligation, and engagement of CD4 coreceptor molecule
(14–17, reviewed in 18). In addition to these regulatory in-
fluences, the cytokines to which APCs and T cells are ex-
posed during differentiation of the naive T cell are also a
potent influence. Thus, IL-12 and IFN-
 
g
 
 favor Th1 differ-
entiation and inhibit the emergence of Th2 cells (11–13,
19, 20). In contrast, the presence of IL-4 early during prim-
ing stimulates Th2 development and represses the produc-
tion of Th1 cells and their characteristic cytokine products
(21, 22). Data from in vitro systems indicate that there are
conditions under which IL-4 can promote the differentia-
tion of purified small, resting T cells into Th2 cells (6). Im-
portantly, however, the ability of these cytokines to influ-
ence the development of CD4
 
1
 
 T cells in vivo has been
studied almost exclusively in systems in which both APCs
and naive precursor T cells are affected (23, 24). Thus, the
relative contributions of T cell–autonomous signaling by
IL-4 and its effects on APCs during immune responses in
vivo remain to be established.
In this regard, previous work has established that, al-
though IFN-
 
g
 
 may have some direct effects on T cell de-
velopment (25), inhibition of IFN-
 
g
 
 receptor signaling in
the T lineage had little effect on Th1 development (26). In
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contrast, targeting such inhibition to macrophages dramati-
cally decreased Th1 development (26). Absence of inter-
feron regulatory factor 1 (IRF-1)
 
1
 
 from APCs led to a sim-
ilar diminution in Th1 development and a deficit of Th1
function in vivo (27, 28). However, it is unclear to what
extent IL-4 acts on APCs in promoting Th2 development
in vivo. In light of the potent ability of IL-4 directly to in-
duce the CD28 ligands B7-1 and -2 (29) and to increase
the rate of synthesis of class II MHC proteins (30, 31), a
critical role of IL-4 in Th2 development could be mediated
through changes in the strength of TCR and CD28 signal-
ing (14, 16, 18). Moreover, under some circumstances
IL-4–deficient T cells develop cytokine production charac-
teristics consistent with the Th2 phenotype (32, 33). Taken
together, these findings raise the question whether the role
of IL-4 in promoting Th2 development under in vivo con-
ditions would be promoted if IL-4 signaling were initially
restricted to activated naive T cells and did not affect
APCs. In addition, an apparent gain-of-function mutation
in the human IL-4R
 
a
 
 chain is associated with atopic dis-
eases (34), thus raising the question whether altered pat-
terns of IL-4R signaling in T cells could potentiate allergic
disease on an otherwise resistant genetic background.
To investigate such questions concerning in vivo regula-
tion of the balance of types 1 and 2 T cells, we have created
lines of mice in which the T lineage expresses a chimeric
cytokine receptor. Specific portions of the human IL-4R
 
a
 
cytoplasmic tail are competent to transduce signals character-
istic of IL-4 when fused to human IL-2R
 
b
 
 and a portion of
its intracellular domain (35). To permit binding of mouse
IL-2 and avoid potential confounding influences from cyto-
plasmic portions of IL-2R
 
b
 
, we have generated a translational
fusion between the extracellular and transmembrane domain
of the mouse IL-2R
 
b
 
 chain and the complete intracellular
domain of mouse IL-4R
 
a
 
. This chimeric receptor transduced
signals characteristic of IL-4 (signal transducer and activator of
transcription [Stat]6 activation) in response to IL-2 binding.
Such signaling was enhanced by activation of thymocytes or
T cells, presumably due to the known role of IL-2R
 
a
 
/CD25
in mouse IL-2 binding and function (36–38). Cells from these
transgenic (Tg) mice exhibited enhanced Th2 responses (IL-4
and IL-5 production as well as help for IgE production). This
influence on the development of effector T cells was suffi-
cient to overcome the resistance of C57BL/6 mice to OVA-
induced allergic airway disease. Thus, it is likely that in mice
expressing the chimeric receptor transgene, the presence of
IL-2 upon antigen challenge favors differentiation of naive T
cells into Th2 effector cells by activation, and that this initially
cell-autonomous pathway can augment Th2 effector function
mediated by IL-4 signals in T cells. 
 
Materials and Methods
 
Reagents. 
 
Cells were cultured in RPMI 1640 supplemented
with 10% fetal bovine serum, sodium bicarbonate, 2 mM 
 
l
 
-glu-
tamine, nonessential amino acids, penicillin/streptomycin (all
from GIBCO BRL, Gaithersburg, MD), and 5 
 
3 
 
10
 
2
 
5 
 
M 2-mer-
captoethanol (Sigma Chemical Co., St. Louis, MO), as described
previously (39). Unmodified and fluorochrome- or biotin-conju-
gated antibodies against IL-2R
 
b
 
/CD122 (unconjugated or FITC-
labeled), CD4 (FITC, r-PE, and biotin), B220 (r-PE), CD3 (un-
conjugated and r-PE), I-A
 
b,d
 
 (FITC, r-PE, and biotin), CD11b
(FITC and biotin), CD11c (r-PE), IL-4 (r-PE), IFN-
 
g
 
 (FITC),
goat anti–rat Ig (biotin), and CD28 (unconjugated) were ob-
tained from PharMingen (San Diego, CA). Biotin-conjugated
anti–mouse CD122 was generated from azide-free preparations of
anti-CD122 (PharMingen) using biotin-amidocaproate 
 
N
 
-hydroxy-
succinimide ester (Sigma Chemical Co.). Streptavidin-PE and
streptavidin-PerCP were obtained from BioSource International
(Camarillo, CA) and Becton Dickinson & Co. (Mountain View,
CA), respectively. Antibodies against Stat5 and Stat6 for electro-
phoretic mobility supershift assays were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Purified or biotinylated mono-
clonal antibodies for cytokine ELISA (IL-4, IL-5, and IFN-
 
g
 
)
were obtained from PharMingen.
 
Plasmid Construction and Generation of Tg Mice. 
 
The chimeric IL-
2R/4R cDNA was constructed by reverse transcriptase–PCR. In
brief, sequences encoding the extracellular and transmembrane
regions of murine IL-2R cDNA were amplified using PFU poly-
merase. The sense oligonucleotide primer corresponded to the
5
 
9
 
-flanking sequence and signal peptide (86–113 bp based on ref-
erence 40: 5
 
9
 
-CCTGAATTCCTCTCAGCTGTGATGGCTA-
3
 
9
 
) with additional nucleotides encoding an EcoRI site. The
antisense oligonucleotide primer corresponded to 908–927 bp,
including a naturally occurring KpnI site at the downstream end
(5
 
9
 
-CCAAGGTACCGGCACTTGAC-3
 
9
 
). The complete intra-
cytoplasmic domain of IL-4R cDNA was amplified from cDNAs
using primers based on a published mouse IL-4R
 
a
 
 cDNA se-
quence (41), except that a KpnI site was introduced at the up-
stream end to permit ligation to EcoRI, KpnI-digested IL-2R
 
b
 
amplicon. After amplification, proteinase K digestion, and cleav-
age with appropriate restriction endonucleases, these two PCR
products were cloned by three-way ligation into the mammalian
expression vector pcDNA3. After verification of expression and
function in the M12 B lymphoma cell line, the cDNA was shut-
tled into a BamHI-digested, 5
 
9
 
-end–filled transgene vector. The
transgene generated by subcloning the chimeric receptor cDNA
into the T lineage–specific vector p1017 (lck proximal promoter
followed by exons, introns, and polyadenylation signal derived
from the human growth hormone gene) (42) was released as a
NotI fragment encompassing the tissue-specific transcription unit,
purified by standard protocols, and microinjected into the pronu-
clei of C57BL/6 
 
3 
 
DBA/2 zygotes. Mice were maintained in ac-
cordance with federal and state government regulations after in-
stitutional approval. Founder lines were propagated by sequential
backcrossing to C57BL/6 and, in later experiments, C57BL/
10.D2 mice for these studies.
 
Northern Blot Analyses.
 
RNA was prepared from splenocyte
suspensions stimulated under the indicated conditions according
to the manufacturer’s protocol after harvest and lysis in TriZol
acid-phenol reagent (GIBCO BRL). These total cellular RNAs
prepared by chloroform extraction and isopropanol precipitation
were resolved on 1.1% agarose gels in the presence of formalde-
hyde, transferred to HyBond-N membranes (Amersham Pharma-
cia Biotech, Inc., Piscataway, NJ) and subjected to hybridization
using gel-purified cDNA probes labeled by a random-primer
technique. A 2.4-kb EcoRI, BamHI fragment spanning the full
chimeric cDNA was used to detect the chimeric cytokine recep-
 
1
 
Abbreviations used in this paper:
 
 IRF, interferon regulatory factor; NTg, non-
transgenic; Stat, signal transducer and activator of transcription;Tg, transgenic. 
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tor (as well as endogenous IL-4R
 
a
 
 and IL-2R
 
b
 
 bands), whereas a
255-bp cDNA fragment generated by reverse transcriptase PCR
was used to detect GATA-3. The GATA-3 cDNA probe was
purified after amplification (60 s each at 94, 58, and 72
 
8
 
C for 35
cycles) using cDNAs prepared from IL-4–stimulated splenocytes
and the oligonucleotides 5
 
9
 
-GAAGGCATCCAGACCCGAAAC
and 5
 
9
 
-ACCCATGGCGGTGACCATGC as primers.
 
Flow Cytometry and Detection of Intracellular Cytokines.
 
To ana-
lyze development and subsets of T lymphoid cells, suspensions of
lymphoid cells were counted, prepared, stained with fluoro-
chrome-conjugated mAbs, and analyzed as described (39). Due to
the weak staining of mouse IL-2R
 
b
 
 (CD122), the indicated sam-
ples were analyzed using fluorochrome-conjugated T lineage
markers and indirect immunofluorescent staining of IL-2R
 
b
 
 us-
ing unlabeled anti-CD122 followed by biotinylated goat anti–rat
Ig, and then streptavidin–r-PE. To enhance CD122 staining in
experiments involving APCs, indirect immunofluorescence was
performed using biotinylated anti-CD122 followed by streptavi-
din–r-PE or PerCP, and larger cells were included in the initial
forward and side scatter gate. For detection of cytokine produc-
tion by staining intracellular pools, lymph node cells were stimu-
lated with immobilized anti-CD3 (10 
 
m
 
g/ml), anti-CD28 (2
 
m
 
g/ml), and recombinant mouse IL-2 (20 ng/ml) for 40 h. Mon-
ensin was added to the cell culture in the last 4 h. Cells were then
stained with anti-CD4-biotin (PharMingen) and streptavidin-
PerCP (Becton Dickinson & Co.), permeabilized according to
the manufacturer’s instructions, stained with both anti-IL-4–PE
and anti-IFN-
 
g
 
–FITC (PharMingen), and analyzed by flow cy-
tometry.
 
Gel Mobility Shift Analyses. 
 
Whole cell extracts were pre-
pared from splenocyte suspensions (43, 44) stimulated under the
indicated conditions using concanavalin A (Sigma Chemical Co.),
purified recombinant mouse IL-4 (R & D Systems, Inc., Minne-
apolis, MN), mouse IL-2 (R & D Systems and PharMingen), and
human IL-2 (Cetus Corp., Emeryville, CA, courtesy of the Bio-
logical Response Modifiers Program). In brief, cells were lysed at
4
 
8
 
C using 0.5% NP-40 supplemented with 0.15 M NaCl, 50 mM
NaF, 1 mM dithiothreitol, 0.1 mM Na-vanadate, 0.4 mM phe-
nylmethylsulfonyl fluoride, 5 
 
m
 
g/ml aprotinin, and 1 
 
m
 
g/ml leu-
peptin, followed by pelleting insoluble materials. DNA binding
reactions were performed using 5 
 
m
 
g of protein in 20 
 
m
 
l reactions
containing 1 
 
m
 
g poly dI-dC competitor and the indicated 
 
32
 
P-
labeled oligonucleotide, essentially as described (43, 44). Double-
stranded oligonucleotides used contained the “N4” Stat6 binding
site from residues 
 
2
 
122 to 
 
2
 
104 of the germline epsilon pro-
moter in the immunoglobulin heavy chain locus, 5
 
9
 
-AAC
 
TTC
 
-
CCAA
 
GAA
 
CAGA and its complement (44), or the “N3”
gamma-activated sequence from the IRF-1 promoter, 5
 
9
 
-CCT-
GAT
 
TTC
 
CCC
 
GAA
 
ATGAT and its complement (45). Identifi-
cation of components in a DNA–protein complex was performed
by supershift analyses using 1 
 
m
 
g per binding reaction of antibod-
ies against either Stat5 or Stat6 (Santa Cruz Biotechnology).
DNA–protein complexes were resolved on a 4.5% nondenaturing
polyacrylamide gel in Tris-borate-EDTA buffer as described (44).
 
Cytokine Assays by ELISA.
 
Lymph node cells were stimu-
lated with immobilized anti-CD3 (10 
 
m
 
g/ml) and either soluble
anti-CD28 (5 
 
m
 
g/ml) or recombinant mouse IL-2 (20 ng/ml) in
the presence or absence of neutralizing polyclonal antibody to
mouse IL-4 (10 
 
m
 
g/ml; R & D Systems) as indicated. Similar re-
sults were obtained using a mAb against IL-4 (11B11; PharMin-
gen). After culture for 6 d, cells were washed and restimulated
with immobilized anti-CD3 plus anti-CD28 for 24 h before col-
lection of culture supernatants for determination of cytokine pro-
 
duction. To measure primary responses of T cells, suspensions of
lymph node cells were cultured with immobilized anti-CD3 (10
 
m
 
g/ml) and either anti-CD28 (2.5 
 
m
 
g/ml) or recombinant mouse
IL-2 (20 ng/ml) for 48 h. Cytokine (IL-4, IL-5, and IFN-
 
g
 
) levels
from culture supernatants were determined by standard sandwich
ELISA according to the manufacturer’s instructions (PharMin-
gen) and standardized to purified recombinant cytokines (Phar-
Mingen for IL-4 and IFN-
 
g
 
; purified recombinant mouse IL-5
was a gift from DNAX, Palo Alto, CA).
 
Immunization of Mice with OVA and Antibody Measurement.
 
After obtaining preimmune sera, mice were injected intraperito-
neally with OVA (10 
 
m
 
g adsorbed on 20 mg aluminum hydrox-
ide; Sigma Chemical Co.). After 7 d, sera were collected from
immunized mice, and then analyzed by isotype-specific ELISA to
determine levels of OVA-specific and total antibodies. In brief,
ELISA plates (Corning Glass Works, Corning, NY) were incu-
bated overnight at 4
 
8
 
C with 50 
 
m
 
l of capture antigen solution (20
 
m
 
g/ml OVA for OVA-specific antibody measurements; sheep
anti–mouse IgE [Serotec
 
 
 
Ltd., Kidlington, Oxford, UK] or anti–
mouse IgG2a [Southern Biotechnology Associates, Birmingham,
AL] for total isotype determinations). After discarding coating so-
lutions, the plates were blocked with 1% BSA in PBS (2 h at
room temperature) and washed. Mouse serum or standard anti-
bodies diluted in PBS containing 0.3% BSA were added to each
well. Antiserum against OVA, mouse IgE (affinity purified from
mouse serum immunized with DNP; Sigma Chemical Co.) or
mouse IgG2a were used as standards for OVA-specific, total IgE,
or total IgG2a ELISA, respectively. Plates were then incubated
for 2 h at room temperature, washed, and incubated with biotin-
ylated detection antibodies (rat monoclonal anti–mouse IgE-biotin
[BioSource International] or anti–mouse IgG2a-biotin) for 1 h,
washed and incubated with avidin–alkaline phosphatase (Sigma
Chemical Co.). Alkaline phosphatase activity was determined
with phosphatase substrate tablets (Sigma Chemical Co.) and as-
sessed during the linear phase of the reaction using an ELISA
reader (SLT-Tecan US, Inc., Durham, NC) at 420 nm and Del-
taSoft 3 analytical software. Each sample was tested in duplicate
and the mean value recorded.
 
Allergic Airway Disease. 
 
Mice (chimR Tg or nontransgenic
[NTg], as indicated; 4-wk-old pups from the third backcross to
C57BL/6) received a priming injection of OVA (10 
 
m
 
g in alumi-
num hydroxide, intraperitoneally) on day 0. These mice under-
went a series of eight daily exposures (40 min each) to an aerosol
generated from OVA (chicken OVA, grade V, Sigma Chemical
Co.; 1% in low-endotoxin, sterile PBS), starting at day 14. The
day after their eighth inhalation treatment, lung mechanics were
measured in these sensitized mice and in controls that were not
exposed to OVA using mechanical ventilation in a body plethys-
mography chamber. After cannulation of the internal jugular
vein, intravenous methacholine (a bronchoconstrictor) was ad-
ministered in the indicated escalating doses (46, 47), with inter-
vals between doses to allow return of pulmonary parameters to
baseline. Each resistance value represents the average of 10 mea-
surements obtained during the peak of a response. After the final
dose, cells were collected by bronchoalveolar lavage, counted,
and analyzed by Wright staining.
 
Results
 
Targeted Expression of a Chimeric Cytokine Receptor in T
Lineage Cells of Tg Mice.
 
Earlier in vivo studies have shown
that systemic IL-4 has the capacity to inhibit the develop- 
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ment of Th1 cells while promoting the Th2 phenotype
(23, 24). However, it is not clear during such IL-4 expo-
sure in vivo what are the relative contributions of IL-4 sig-
naling within the T cell versus those in APCs. Moreover, T
cells differentiated under strong polarizing conditions in
vitro retained their characteristics after transfer in vivo (48),
but the extent to which different levels of IL-4 signaling
within T cells affect Th1 or Th2 development before ex-
ogenous antigen challenge is unknown. To investigate
these questions, and to determine if enhanced IL-4 signal-
ing after activation of naive T cells could create susceptibil-
ity to allergic diseases in vivo (34), we created a chimeric
cytokine receptor that could bypass the function of endog-
enous IL-4 receptors.2 Because mouse IL-2 binds poorly to
human IL-2 receptors, this chimeric receptor was designed
as a translational fusion of the ligand-binding and trans-
membrane domains from the mouse IL-2Rb chain and the
intracellular domain of the mouse IL-4Ra (Fig. 1 A).
The IL-2 and IL-4 receptors share a number of architec-
tural principles. IL-2Rb and IL-4Ra are in the same sub-
family of hematopoietin receptors, each binds to the Janus
kinase Jak1, and the receptors share a gc chain, leading to
Jak3 recruitment (49). Despite these features, they activate
different Stat transcription factors and appear to differ in
their respective potency for activation of mitogen-activated
protein kinase and insulin receptor substrate pathways (49–
51). Accordingly, transfer of specific domains of human IL-
4Ra onto a 140-amino acid cytoplasmic signaling domain
from human IL-2Rb was sufficient for IL-2 induction of
CD23 on B cells, a response characteristic of IL-4 but not
IL-2 (35). An additional important consideration is that,
unlike the human IL-2/IL-2R system, mouse IL-2 is re-
ported to bind mouse IL-2Rb and activate resting T cells
poorly unless IL-2Ra is expressed (36–38). Consistent
with this possibility, M12 B lymphoma cells stably trans-
fected with our chimeric receptor cDNA demonstrated
that this receptor transduced IL-4–specific signals (Stat6
activation, induction of CD23 and the Ig germ line e pro-
moter), but only when the IL-2Ra chain, a protein virtu-
ally absent from resting naive T cells and from most thy-
mocytes, was also transfected.2 This dependency of the
mouse IL-2Rb chain on IL-2Ra expression implied that
the chimeric receptor molecule might not bind IL-2 effi-
ciently until a cell was induced to express IL-2Ra chain,
thus providing a mechanism to protect thymocyte and T
cell development from abnormalities induced by IL-4 (42).
Since IL-2 is a ligand that will be present at high concen-
tration early after activation of naive T cells, these features
suggested that a mIL-2Rb/mIL-4Ra chimera might acti-
vate IL-4–specific signals in the absence of IL-4, but would
signal inefficiently before T cell activation.
In light of these findings, we created Tg mice in which
expression of this chimeric receptor was targeted to the T
lymphoid lineage using the T lineage–specific regulatory
sequences of the lck proximal promoter, thus facilitating an
investigation of the regulatory roles of IL-4 signaling in
mouse T lineage cells. Different copy-number integrations
on the X chromosome were bred from founders; the phe-
notype in each of these lines is similar to the others (data
not shown). Transgene-positive progeny expressed trans-
gene-encoded transcripts in thymocytes and unfractionated
splenocytes (Fig. 1 B). When peripheral lymphoid cells 2Youn, J., et al., unpublished observations.
Figure 1. Targeted expression of the chimeric IL-2Rb/IL-4Ra trans-
gene to T-lineage cells. (A) Structure of chimeric cytokine receptor
cDNA. The chimeric IL-2R/4R receptor was composed of extracellular
domain and transmembrane domain of mouse IL-2Rb, linked to the
complete intracellular domain of IL-4Ra. Tyrosine residues and two
acidic domains (ID-1 and I4R) in the IL-4Ra intracytoplasmic tail are in-
dicated. (B and C) Expression of chimeric receptor transcripts in T-lin-
eage cells from Tg mice. RNA was prepared from NTg and Tg mice
(right) (second backcross generation to B6) using the indicated lymphoid
organs (B and C) or purified T or B cells (C), and from M12 B lymphoma
cells (parental, 2, or transfected, 1, with the chimeric receptor cDNA) as
indicated. Splenic T and B cells were separated by nylon wool column,
and B cells were further purified by magnetic activated cell sorting
(MACS) using streptavidin-microbeads after labeling with a biotinylated
anti-B220 mAb. Purity determined by flow cytometry was z80% CD31
(T cells) or 95% B2201 (B cells). RNA was resolved on a formaldehyde-
agarose gel, transferred to HyBond filters, and probed with 32P-labeled
DNA comprising the IL-2Rb and IL-4Ra sequences present in the Tg
cDNA. (C) Arrows denote the position of RNAs encoded by the trans-
gene, two of which comigrated with endogenous RNAs hybridizing to
the IL-2Rb 1 IL-4Ra probe as indicated; the positions of these RNAs
are also marked by open circles. An asterisk marks the band of intermedi-
ate mobility unique to transgene-positive animals (lane 2).1807 Youn et al.
were fractionated into T and B cells and subjected to
Northern blot analyses, there was no difference in intensity
of a band representing endogenous RNA in Tg and NTg
samples and no band at the position of the chimeric tran-
script could be detected in the B2201 cells purified from
Tg mice (Fig. 1 C; a transgene-specific RNA species mi-
grates at a position [*] between two bands containing en-
dogenous RNAs [o]). In FACSÒ analyses, nearly all thy-
mocytes and CD41 cells from male Tg mice expressed the
IL-2Rb epitope (CD122) at their cell surface, whereas ex-
pression of endogenous IL-2Rb chains was observed only
on a smaller fraction of those cells in NTg littermates (Fig.
2 A). Of note, the level of CD122 staining on Tg thy-
mocytes and T cells was similar to the staining intensity of
positive cells among wild-type samples; the main difference
was in the frequency of positive cells. Since the staining in-
tensity of CD122 on Tg T cells (chimeric receptors plus
endogenous IL-2Rb) appeared at most fourfold greater
than on wild-type cells (endogenous IL-2Rb alone), these
findings suggest that the number of chimeric receptors is
only a few times higher than a cytokine receptor such as
endogenous IL-2Rb (Fig. 2 B). Consistent with the North-
ern blot data, direct immunofluorescent antibody staining in-
dicated that among cells competent to express the IL-2Ra
chain, CD31 cells expressed the IL-2Rb epitope at levels
higher in Tg mice than in their NTg littermates, whereas
Tg B2201 cells did not (Fig. 2 B). Moreover, the level of
CD122 on I-A1B2202 cells and populations labeled with
cell-surface epitopes that mark macrophages (CD11b1
CD11c1) and dendritic cells (CD11b2CD11c1) was no dif-
ferent in Tg animals and wild-type controls, whereas in-
creased CD122 expression was readily detected in the T
cell-enriched (I-A2B2202) gate of Tg samples (Fig. 2 C).
We conclude that expression of the chimeric cytokine re-
ceptor transgene in lymphoid cells is restricted to the T lin-
eage.
Intact Development and Deployment of the T Lineage.
Overexpression of IL-4 in thymocytes using the lck proxi-
mal promoter caused a dramatic decrease in thymic cellu-
larity and led to a failure of export of CD8 single positive
cells to populate peripheral sites (42). Accordingly, it was
possible that the chimeric cytokine receptor transgene
would lead to similar derangements. Alternatively, if it
were functionally inert in resting T cells and most thy-
mocytes (which do not express IL-2Ra protein/CD25), T
lineage development and deployment should be normal.
This latter possibility would be consistent with reports that,
unlike human IL-2Rb, mouse IL-2Rb cannot signal pro-
liferation of resting thymocytes or CD41 T cells (36–38).
Indeed, the size and balance of thymic populations in Tg
mice were no different from thymic profiles of their NTg
littermates. Moreover, although there was a subtle variation
in the CD4/CD8 ratio (Tg, 2.5 6 0.4 vs. NTg, 1.7 6 0.1),
CD41 and CD81 T cells populated the spleen and lymph
Figure 2. Cell surface expression of chimeric receptor molecules on thymocytes and peripheral T cells from Tg mice. (A) Representative fluorescence
histograms from thymocytes and lymph node cells of NTg or Tg mice were sequentially stained with rat anti–mouse IL-2Rb, biotinylated goat anti–rat
Ig, and then streptavidin-PE (three-layer staining). Lymph node cells were costained with anti-CD4. Heterozygous females exhibited the effects of Lyon-
ization, with high-level expression of IL-2Rb protein on only 50% of thymocytes. However, the alterations (cytokine production; allergic airway disease)
reported below were observed in both males and females. The data presented were from second backcross generation mice; similar results were observed
using N1- and N3-generation mice. (B) Lymph node cells were costained with anti–mouse IL-2Rb-FITC and either anti-CD3-PE or anti-B220-PE as
indicated. The profiles represent the fluorescence intensity of cells from the lymphocyte gate (FSC and SSC) and CD41, CD31, or B2201 gate, as in-
dicated. (C) Splenocytes (a–f), or metrizamide gradient-enriched APCs (g–j), from wild-type (NTg) and chimeric receptor transgene-positive (Tg) mice
(N3 generation) were subjected to three-color indirect immunofluorescent staining as indicated, and then analyzed by flow cytometry. Uniform compen-
sations and a uniform forward and side-scatter gate were applied to all samples. CD122 staining in the T cell-enriched gate (a and b; I-A and B220 nega-
tive) demonstrated expression of the transgene. Higher levels of autofluorescence were present in the APC-enriched populations (c–j) due to differences
between the larger APCs and lymphoid cells, thereby leading to broader CD122 histograms. In all APC-gated samples, the mean fluorescence intensity
(MFI) for CD122 in Tg samples was less than the MFI of the wild-type controls. The same results were obtained using anti-CD122 directly conjugated
with fluorescein and appropriate staining combinations for APC markers.1808 In Vivo Function of an IL-2R/IL-4R Chimera
nodes in normal numbers (Fig. 3). Although lck may be
expressed in the natural T cell compartment of NK1.1-
positive TCR-a/b–bearing T cells (52), there was no dif-
ference between Tg mice and wild-type (NTg) littermates
in the number of these cells (data not shown). Thus, T cell
development appears normal despite the potential for the
chimeric cytokine receptor to deliver IL-4–like signals.
IL-4–independent Induction of Stat6 DNA Binding Activity
in Tg T Cells. The finding that T cell development was
normal provided evidence, albeit indirect, that signaling by
the chimeric receptor may be IL-2Ra dependent. To de-
termine directly if the transgene mediates Stat6 activation
under conditions that bypass potential influences from en-
dogenous IL-4 receptors, we performed mobility shift as-
says using thymocytes and spleen cells that were freshly iso-
lated or first exposed to activating stimuli (Fig. 4 and data
not shown). Using an oligonucleotide probe whose spacing
of the consensus repeat TTC/GAA permits stable binding
by Stat6 but not Stat1–Stat5, binding activity was induced
in resting spleen cells with addition of exogenous IL-4 (Fig.
4 A, lanes 5 and 10), whereas mouse IL-2 at 10 ng/ml
(z0.67 nM, near the Kd of an IL-2R bg dimer, 1 nM) did
not activate Stat6 in resting thymocytes or splenocytes
(lanes 2 and 7) from Tg mice or controls. Higher concen-
trations of mouse IL-2 (100 ng/ml) or human IL-2 (106
Cetus U/ml; z300 ng/ml) were sufficient to generate nu-
clear Stat6 binding activity (lanes 3, 4, 8, and 9), whose rel-
atively low level may reflect inefficient activation through
bg dimers at concentrations well above their Kd, as well as
the presence of B cells, which lack chimeric receptor ex-
pression (Fig. 2). In contrast to resting cells (Fig. 4 B, lanes
1–6), activation (“priming”) and production of IL-2 in the
cultures triggered efficient Stat6 induction in Tg (lanes 10–
12) but not NTg cells (lanes 7–9). Similar results were ob-
tained when neutralizing antibodies against IL-4 were in-
cluded during the activation phase of the culture (Fig. 4 B,
lanes 13–18). The presence of Stat6 in the mobility shift
complex was confirmed by supershifting with antiserum
specific for Stat6, whereas anti-Stat5 failed to create a
slower mobility complex when using this Stat6-specific oli-
gonucleotide probe (Fig. 4 C). IL-2–dependent Stat6 in-
duction in Tg cells was also observed for activated thy-
mocytes, confirming its association with the T lineage of
chimeric receptor Tg mice (Fig. 4 D). To determine the
effect of the transgene on induction of an IL-4 target gene
in T cells, we performed Northern blot analyses of the levels
of GATA-3 mRNA, a transcription factor whose levels in-
crease in IL-4–treated T cells and during Th2 differentia-
tion (53). In contrast to the results with wild-type mice, ac-
tivation of lymphoid cells from chimeric receptor Tg mice
led to substantial induction of GATA-3 without the addi-
tion of exogenous IL-4 (Fig. 4 E). These data do not provide
quantitation of the biochemical efficiency of the IL-2Rb/
IL-4Ra chimera. Since the flow cytometric data suggest
that there is a modest (less than fourfold) excess of chimeric
receptors relative to wild-type CD122, our chimeric receptor
may induce Stat6 less efficiently than endogenous IL-4Ra
chains. Notwithstanding this possibility, we can conclude
that upon activation in the absence of exogenous IL-4, T
cells from Tg mice exhibit increased signaling characteristic
of IL-4 compared with their NTg counterparts.
Development of Type 2 T Effector Cells from Precursors. In
light of this evidence that the chimeric receptor is func-
tional in T cells, we tested whether the transgene could in-
fluence the development of Th1 or Th2 cells during in
vitro stimulation (Fig. 5). Cells from Tg mice produced
over 10-fold more IL-4 than those from their NTg litter-
mates when lymph node cells were stimulated through the
TCR and costimulatory CD28 molecule for 6 d, washed,
and restimulated. When effector cells developed in the
presence of neutralizing antibodies against IL-4 during the
primary culture, this difference between Tg and NTg mice
was more dramatic (33-fold), reflecting a greater inhibitory
effect of anti–IL-4 on the NTg samples. Consistent with
reports that IL-4–deficient mice can generate Th2-like cells
(32, 33), some IL-4 production was still observed under
these conditions, perhaps reflecting the important role of
costimulation through CD28. Indeed, although the output
of IL-4 was diminished if anti-CD28 was omitted from the
differentiation phase of these cultures, lymph node cells
from chimeric receptor Tg mice exhibited a far greater
competence to generate IL-4–producing effector cells when
compared with their wild-type littermates. Similar, albeit
less dramatic, results were obtained when IL-5 production
by these cultures was used as an indicator of effector T cell
development. Despite the potentiation of IL-4 production
conferred by this diversion of IL-2 binding into signaling
pathways characteristic of IL-4, IFN-g production was not
suppressed. However, addition of exogenous IL-4 to simi-
lar cultures has led to variable inhibition of IFN-g produc-
Figure 3. Normal development in the T lineage. Suspensions of (A)
thymocytes and (B) splenocytes were subjected to staining for CD4 and
CD8, as indicated. Fluorescence histograms from a representative Tg
male, heterozygous female, and NTg littermate are shown. The absolute
numbers of thymocytes (NTg, 176 3 106; Tg, 180 3 106), splenocytes
(NTg, 74 3 106; Tg, 83 3 106), T cells, and their subsets were not signif-
icantly different in Tg and NTg animals.1809 Youn et al.
tion (data not shown). Taken together, these results indi-
cate that development of the Th2 phenotype in T cells
from chimeric receptor Tg mice is potentiated, and indeed
can be largely independent of endogenous IL-4. Of note,
under these conditions the original difference between Tg
and NTg cells in levels of IL-4 signaling is confined to the
T cells.
Increased Type 2 Cytokine Response and Help to Antibody
Production.  The above data demonstrate that expression
of the transgene is able to influence effector T cell develop-
ment in vitro. Given that the transgene amplified IL-4–spe-
cific outcomes during in vitro differentiation of T cells, we
tested its effects on in vivo processes. First, we investigated
this issue by measuring IL-4 and IFN-g production after
short-term polyclonal stimulation of lymph node cells in
vitro, since the cytokines produced under these conditions
are derived predominantly from CD41 T cells expressing
an antigen-experienced/memory phenotype (13, 54–56).
Lymph node cells were stimulated 40 h with anti-CD3 and
either anti-CD28 or exogenous IL-2, or both. Culture su-
pernatants were then subjected to cytokine ELISA (Fig. 6
A), and cells were stained with fluorescein-conjugated anti-
bodies to determine the frequency of IL-4– or IFN-g–pro-
ducing cells (Fig. 6 B). A fourfold increase in IL-4 pro-
duced by Tg cells was observed compared with those from
NTg littermates. Consistent with the in vitro differentia-
tion assays (Fig. 5), Tg cells produced similar or at most
slightly reduced amounts of IFN-g compared with NTg
controls (Fig. 6 A). In concert with these data, lymph node
cells from chimeric receptor Tg mice included 3% IL-4–
producing CD41 T cells, whereas at most 0.3% of CD41
NTg cells exhibited detectable IL-4 (Fig. 6 B; the back-
ground of nonspecific staining in these assays was z0.3% in
the CD41 gate). Display of IFN-g–producing cells re-
vealed only a modest difference between NTg and Tg mice
and demonstrated that the increase in IL-4 production re-
flected an increase in the frequency of cells that produce
IL-4 but not IFN-g, and thus correspond to a Th2 rather
Figure 4. The chimeric receptor induces Stat6 in activated lymphoid
cells. (A) Induction of Stat6 by IL-2. Single cell suspensions of resting
splenocytes from wild-type (NTg) or chimeric receptor transgene-posi-
tive mice (N3 generation) were cultured in complete media supple-
mented (30 min at 378C) with the indicated concentration of purified re-
combinant IL-2 (lanes 2–4 and 7–9), purified recombinant mouse IL-4
(lanes 5 and 10), or without added lymphokine (lanes 1 and 6). Extracts
from these cells were then subjected to mobility shift assays using an oli-
gonucleotide from the mouse Ig germ line e promoter (44), which exhib-
its specificity for Stat6 due to an N4 spacing between the TTC and GAA.
(B) Activation-dependent enhancement of IL-4–independent induction
of Stat6 binding activity. Resting or activated RBC-depleted splenocytes
(N3 generation) were stimulated (30 min at 378C) with either IL-2 or IL-4
as indicated. Where indicated, cells were activated during a 15-h culture
in the presence of Con A (2.5 mg/ml) and IL-2 (10 ng/ml), in the pres-
ence or absence of neutralizing anti–IL-4 antibodies, and then washed be-
fore stimulation with IL-2 or -4. Whole cell extracts were subjected to
mobility shift assays as in A. (C) Stat6 but not Stat5 present in the IL-4–
independent mobility shift complexes. Extracts from activated spleno-
cytes, generated as in A, and then treated with IL-2 (lanes 2, 5 and 8) or
IL-4 (lanes 3, 6, and 9) as indicated, were incubated with antiserum
against Stat5 (lanes 4–6) or Stat6 (lanes 7–9) as indicated. DNA–protein
complexes were then resolved by nondenaturing gel electrophoresis. (D)
Induction of Stat6 in activated thymocytes. Thymocyte suspensions from
Tg mice and wild-type littermates were cultured 15 h in PMA (50 ng/ml)
and ionomycin (1 mg/ml) in the presence of mouse IL-2 (10 ng/ml) and
neutralizing antibodies against mouse IL-4 (10 mg/ml). These activated
cells were then washed and placed in culture with no added cytokine
(lanes 1 and 4), mouse IL-2 (10 ng/ml; lanes 2 and 5), or mouse IL-4 (10
ng/ml; lanes 3 and 6). (E) Induction of GATA-3 mRNA in Tg lympho-
cytes. Portions of lymphoid cell suspensions (pooled spleen and lymph
node) from Tg (N2 generation in this experiment) and NTg mice were
placed in culture (lanes 3–6) or used to prepare RNA without culture
(lanes 1 and 2). RNAs were prepared after culturing cells 48 h in the pres-
ence of immobilized antibodies against CD3 (10 mg/ml), soluble anti-
CD28 (5 mg/ml), and either mouse IL-4 (10 ng/ml; lanes 5 and 6) or the
combination of human IL-2 (10 ng/ml) and neutralizing antibodies
against mouse IL-4 (10 mg/ml) (lanes 3 and 4), as indicated. Northern
blot analyses of equally loaded lanes of RNA (as assessed by hybridization
with an rRNA oligonucleotide; data not shown) were probed for GATA-3
as described in Materials and Methods.1810 In Vivo Function of an IL-2R/IL-4R Chimera
than a Th0 (56) phenotype. Taken together, these data
suggest that the T cell–autonomous signals transduced by
the chimeric cytokine receptor may function in vivo selec-
tively to bias effector T cell development in favor of Th2
cells.
To measure directly the effect of the transgene on an in-
dicator of type 2 help in vivo, we immunized mice with
OVA in aluminum hydroxide. Generation of antigen-spe-
cific IgE requires T cell help and IL-4 (12, 13, 57). It may
normally require days to generate antigen-specific effector
cells that are efficient producers of IL-4, and for the IL-4 to
lead to antibody class switching to the epsilon heavy chain
exons so as to secrete IgE (58, 59). Therefore, we chose
day 7 after immunization as a time point for comparison of
total and antigen-specific IgE levels in chimeric receptor
Tg mice to those in their wild-type littermates (Fig. 7).
Both antigen-specific (Fig. 7 A) and total (B) IgE produc-
tion were elevated in the Tg mice (average of 33- and 11-
fold, respectively). Moreover, total IgE levels in Tg mice
were elevated even before immunization, suggesting that
an increase in type 2 help may be engendered by the chi-
meric receptor transgene during spontaneous evolution of
the lymphoid repertoire in vivo. In contrast, levels of
IgG2a, which is dependent on IFN-g and thus favored by
type 1 help, were little different in Tg mice from NTg lit-
termates before immunization, and after immunization
were indistinguishable from NTg controls (Fig. 7 C).
These results provide in vivo evidence that T cell–specific
expression of the transgene confers a selective enhancement
of type 2 help, and suggest the possibility that this effect
might be uncoupled from inhibition of type 1 help in vivo.
Moreover, our data suggest that T cell activation that oc-
curred spontaneously may have induced a bias toward pro-
vision of type 2 help in Tg mice before antigen challenge.
Importantly, when Tg mice were rechallenged with OVA
5 wk after their first immunization, their IgE anti-OVA re-
call response remained dramatically greater than that of
NTg controls (Fig. 8). These results indicate that the trans-
gene-imposed bias in the helper arm of a response to a spe-
cific antigen is sustained in a recall response.
Figure 5. Enhanced IL-4–independent Th2 development during in
vitro T helper cell differentiation. Lymph node cells from a pool of three
NTg or Tg littermates (N3 generation) were stimulated with immobilized
anti-CD3 (10 mg/ml) and either anti-CD28 (2 mg/ml) or recombinant
mouse IL-2 (20 ng/ml) in the presence or absence of polyclonal antibody
to mouse IL-4 (10 mg/ml), as indicated. After 6 d of culture, cells were
washed and restimulated with immobilized anti-CD3 plus anti-CD28 for
24 h. Supernatants were collected and analyzed by ELISA as described in
Materials and Methods. These figures are representative of more than
three (for IL-4 and IFN-g) or two (for IL-5) independent experiments.
Additional experiments using lymph node cells from individual mice of
each subline showed no differences in the penetrance of the observed ef-
fects on cytokine (IL-4, IFN-g) production.
Figure 6. Enhanced Th2 cytokines in early primary responses. (A)
Lymph node cells, as in Fig. 5, were stimulated 48 h as indicated and su-
pernatants were collected. IL-4 and IFN-g levels in supernatants were
measured by ELISA. These figures are representative of three indepen-
dent experiments; additional experiments using preparations of lymph
node cells from individual mice of each subline showed no differences in
the penetrance of the observed effects on cytokine (IL-4, IFN-g) produc-
tion. (B) Lymph node cells, as in Fig. 5, were stimulated with immobi-
lized anti-CD3 (10 mg/ml), anti-CD28 (2 mg/ml), and recombinant
mouse IL-2 (20 ng/ml) for 40 h. Monensin was added to the cell culture
in the last 4 h. Cells were stained with anti-CD4-biotin and streptavidin-
PerCP, permeabilized, and stained with both anti-IL-4–PE and anti-IFN-
g-FITC, followed by FACSÒ analysis. These figures are representative of
histograms in two independent experiments.1811 Youn et al.
OVA-inducible Airway Hyperresponsiveness Due to Chimeric
Cytokine Receptor Expression. In light of the findings that
one parameter of type 2 help in response to a specific anti-
gen was increased in chimeric cytokine receptor Tg mice,
we tested whether this effect could be sufficient to enhance
an allergic response (Fig. 9). After intraperitoneal sensitiza-
tion with OVA, followed by daily OVA inhalations,
BALB/c mice acquire airway hyperresponsiveness to meth-
acholine (46, 47, 60, 61). This T cell–dependent hyperre-
sponsiveness is accompanied by eosinophilic airway infiltra-
tion and evidence of type 2 help (60, 61). In contrast to the
BALB/c background, C57BL/6 mice develop an eosino-
philic infiltrate, but less IL-4 production and minimal air-
way hyperresponsiveness, measurable as increased lung re-
sistance (61, 62). Consistent with previous reports, the lung
resistance of OVA-sensitized NTg littermates was no dif-
ferent than that of unsensitized mice (Fig. 9 A). In contrast,
lung resistance after bronchoconstrictor challenge (Fig. 9
A) and airway eosinophilia (B) were increased in chimeric
receptor Tg mice relative to littermate controls that had
been OVA sensitized at the same time. We conclude that
the chimeric cytokine receptor served as a dominant mo-
nogenic trait capable of intensifying an allergic disease pro-
cess, presumably through enhancement of the development
of type 2 T cells.
Discussion
In vitro findings have identified conditions under which
IL-4 can induce Th2 differentiation among highly purified
T cells. In vivo experiments investigating the contributions
of cytokines to regulating the populations of type 1 (IFN-
g–producing) and type 2 (IL-4–producing) effector T cells
have involved perturbations that affect APCs as well as acti-
vated T cells. In light of the influences exerted by antigen
dose, APC type, and costimulation intensity (13–18), it is
not clear what conditions precisely mimic T cell–APC in-
teractions in vivo. Thus, the ability of IL-4 to promote
Th2 development when the initial perturbation is confined
to the T lineage, and whether this would be sufficient to
enhance allergic disease susceptibility, have not been estab-
lished. We have employed an in vivo strategy that used a
chimeric cytokine receptor to bypass endogenous IL-4 re-
ceptors by broadening the signaling specificity of IL-2. This
approach was combined with the use of a T lineage-spe-
cific promoter to target expression of this receptor as a T
cell–specific transgene, so that the initial in vivo perturba-
tions of signaling are segregated from APC populations (26,
42, and Fig. 2). This diversion of IL-2 binding into IL-4
signaling pathways enhanced type 2 responses. Although a
precise quantitation of the magnitude of activation of IL-4
signaling by the chimeric receptor in comparison to endog-
enous IL-4 receptors cannot be performed, our findings in-
dicate that T cell–autonomous IL-4 signaling in vivo is suf-
ficient to potentiate Th2 development on a C57BL/6
Figure 7. Serum levels of IgE and IgG2a in mice immunized with
OVA. Tg (n 5 6) and NTg (n 5 6) mice (N3 generation) in two inde-
pendent experiments were injected intraperitoneally with 10 mg OVA
adsorbed in aluminum hydroxide (20 mg). 7 d after injection, sera were
collected and levels of OVA-specific and total antibodies were measured
by isotyping ELISA, as described in Materials and Methods. (A) OVA-
specific IgE. (B) Total IgE. (C) Total IgG2a. Each symbol represents each
individual mouse and solid lines (–) indicate the mean value for each
group. Immunization under these conditions elicited minimal OVA-spe-
cific IgG2a responses.
Figure 8. Recall responses of antibody production in mice after second
immunization. Tg (n 5 6) and NTg (n 5 6) mice in two independent ex-
periments were injected intraperitoneally with 100 mg OVA adsorbed to
20 mg aluminum hydroxide. Primary responses measured at 7 d were
similar to those obtained with 10 mg OVA (Fig. 7). The indicated anti-
body levels (mean 6 SEM) were quantified by ELISA using sera obtained
before, and 7 d after, reimmunization with OVA (100 mg in aluminum
hydroxide). (A) OVA-specific IgE. (B) Total IgE. (C) Total IgG2a.1812 In Vivo Function of an IL-2R/IL-4R Chimera
(Th1-oriented) background. Moreover, in vitro evidence
suggests that Stat6 induction by IL-2 treatment of activated,
Tg T cells is no greater than the response of wild-type cells
to IL-4 (Fig. 4). As such, these findings complement and
extend in vitro evidence suggesting that the genetic back-
ground of a T cell is a more important factor in the polar-
ization of effector function than is the source of the APCs
(63).
One current model for the regulated choice of polarized
effector cytokine production divides the process into two
phases. In the first phase, the naive uncommitted precursor
is induced to secrete IL-2 and to activate at least low-level
transcription of IL-4 and IFN-g (64). The magnitude of
IL-4 gene activation in this phase would depend primarily
on the strength of TCR signaling, costimulation, and CD4
engagement (14–18, 56, 65). The initial release of IL-4, or
IFN-g and resultant IL-12, would then result in an amplifi-
cation phase during which Stat6, or Stat1 and Stat4, would
potentiate the differentiation process. In contrast to their
wild-type counterparts, T cells bearing the chimeric recep-
tor transgene could transduce IL-4–specific signals in the
earlier phase due to the presence of IL-2, leading to en-
hanced Th2 development. The observed increase in IgE
levels of chimeric receptor mice before immunization with
an antigen suggests that these early-phase IL-4 signals may
be sufficient to increase the development of effector Th2
cells as the antigen-experienced T cell effector and memory
repertoires evolve in vivo. Since GATA-3 expression in Tg
T cells has been reported to be sufficient to enhance Th2
development (53), the finding that GATA-3 expression is
potentiated after activation of chimeric cytokine receptor-
bearing T cells may provide the mechanistic basis for the T
cell–autonomous increase in Th2 cells. However, other
transcription factors may also be involved in this effect.
In contrast to the increase in IgE, the finding that IgG2a
levels in our Tg mice are essentially normal suggests that
the alteration in signaling caused by chimeric receptor ex-
pression in T cells may not be sufficient to suppress type 1
help in vivo. Moreover, no significant decrease in IFN-g
production by chimeric receptor transgene-positive cells
was observed, even under conditions where Th2 develop-
ment was .30-fold more potent than that of NTg coun-
terparts. Although these data were less conclusive because
of the variable ability of exogenous IL-4 to suppress in
vitro IFN-g production in our samples, they suggest that
when IL-4 signaling during the early activation phase of ef-
fector T cell development is confined to the T cells, en-
hancement of type 2 help may be uncoupled from inhibi-
tion of type 1 help. Consistent with this possibility, transfer
experiments suggest that exposure of APCs to IL-4 in vivo
creates an APC population that does not support Th1 de-
velopment (15). Thus, it is possible that IL-4 action on
APCs may play a role in the inhibition of Th1 develop-
ment, a mechanism analogous to the role of APCs in IFN-
g–induced Th1 development but in contrast to the T cell–
autonomous promotion of Th2 development by IL-4.
Gene knockout experiments have shown that the IL-4–
induced transcription factor Stat6 is involved in inhibition of
the emergence of Th1 cells as well as in Th2 development
(66, 67). A potential explanation of the normal IFN-g pro-
duction and IgG2a is that this inhibitory function of Stat6 is
mediated by its activity in APCs. Since IFN-g acts on
APCs to enhance IL-12 release and promote Th1 develop-
ment (11, 68), one possibility for target gene regulation in
the APCs is that activated Stat6 inhibits induction of inter-
feron-responsive factors such as the transcription factor
IRF-1. In this regard, an intact IRF-1 gene in the APC
population is required for normal Th1 development (27,
28). Moreover, IL-4 can inhibit IRF-1 promoter induction
(69) by a Stat6-dependent mechanism (Goenka, S., J. Youn,
L.-y. Yu-Lee, U. Schindler, and M. Boothby, manuscript
Figure 9. The chimeric cytokine receptor transgene is sufficient to cre-
ate sensitivity to allergic airway disease on a disease-resistant background.
(A) Antigen sensitization of Tg, but not wild-type, mice leads to an in-
creased bronchoconstrictor response. Mice backcrossed to C57BL/6 (N3)
were sensitized to OVA by a single intraperitoneal injection (10 mg in
aluminum hydroxide), followed by a series of antigen inhalations as de-
scribed in Materials and Methods. Control mice were sham sensitized us-
ing PBS. These mice then underwent measurements of lung resistance to
airflow after each of a series of methacholine injections at standard doses
(47). The data represent the mean (6 SEM) values derived from eight
sensitized chimeric receptor Tg mice and an equal number of littermates
in independent experiments. Significance values (comparison of sensitized
Tg and NTg animals) are indicated above the graph at those methacho-
line doses for which differences were observed. (B) Mean values for the
number and distribution of cells recovered after bronchoalveolar lavage of
the lungs of the mice described in A.1813 Youn et al.
submitted for publication). Thus, one mechanism that
could mediate a role for APCs in IL-4–induced repression
of Th1 development is inhibition of IRF-1. A mechanism
that may be T cell–autonomous has been reported to rein-
force inhibition of Th1 development by IL-4 in an in vitro
system. In this model, IL-4 inhibits expression on T cells of
an IL-12 receptor chain (IL-12Rb2) needed for normal
signaling (70). These results were obtained using cells from
BALB/c-background mice, and the extinction of IL-12Rb2
mRNA required z5 d, a time point at which many cells
may already have become committed to IFN-g production
(64, 70). However, our data reflect a C57BL/6 background.
Thus, one possible explanation is that Th1 regulation used
different mechanisms in cells derived from a BALB/c
(Th2-oriented) background as compared with C57BL/6-
derived cells. Also, IL-4 signaling by the chimeric receptor
may primarily occur early during effector cell differentia-
tion, when IL-2 levels are maximal, so that the mechanism
inhibiting Th1 development upon initial T cell activation
may differ from the process in which cells committed to a
Th2 phenotype are rendered unresponsive to IL-12.
An important question underlying these studies is the
degree to which genetic influences that bias the effector T
cell repertoire account for differences in susceptibility to al-
lergic diseases (34, 71). Although it is clear that the effi-
ciency of generating type 2 help can be correlated with sus-
ceptibility of C57BL (B6 or B10.D2) and BALB/c mice to
immunologic diseases (61, 72, 73), it also is clear that sus-
ceptibility arises from complex, polygenic characteristics
and not only from Th1/Th2 regulation (32, 33, 74–76).
For instance, in certain instances BALB/c mice are unable
to heal Leishmania major infection despite inactivation of the
IL-4 gene (32). A reciprocal question relates to the resis-
tance of C57BL/6 mice to airway hyperresponsiveness in
allergic airway disease (61). In particular, it is not clear if
the T cell contribution to allergic disease is exclusively a re-
flection of Th2 development, or if other T cells may be
important (for a review, see reference 77). While previous
studies have shown that transfer of 5 3 106 activated, anti-
gen-specific Th2 cells is sufficient to create susceptibility in
BALB/c mice (78), other data indicate that far fewer anti-
gen-specific T cells normally arise after immune challenge
(79). Moreover, data from other disease models show that
normal resistance is overcome when such large numbers of
cells are used in transfers (80). The present data indicate
that the introduction of a bias toward Th2 development on
a C57BL/6 background is sufficient to potentiate a bron-
choconstrictor response when normal numbers of T cells
are present, the response evolves exclusively from antigen
challenge, and effector cytokines are produced only by
their natural promoters in physiologically appropriate cell
types. Moreover, our findings are consistent with the possi-
bility that a sufficient enhancement of IL-4Ra signaling in
T cells could promote allergic disease susceptibility in hu-
mans (34). These data suggest that one useful application of
the chimeric cytokine receptor transgene will be in simpli-
fying the analysis of disease susceptibility traits. It can be
predicted that of the many loci that contribute to differ-
ences between C57BL (B6 or B10.D2) and BALB/c mice
in disease susceptibility, only some will be involved in reg-
ulation of the balance between Th1 and Th2 cells. Use of
this dominant monogenic trait (the transgene) could facili-
tate identification of those loci that regulate functions other
than effector T cell phenotype. However, it should be
noted that the magnitude of such airway hyperresponsive-
ness was still considerably less than that typically obtained
in BALB/c mice (Aronica, M.A., and J.R. Sheller, unpub-
lished observations). Thus, the susceptibility of the BALB/c
strain to allergic airway disease probably reflects genetic
contributions in addition to its tendency to develop robust
Th2 responses.
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